Innovent Biologics（信达生物制药）

About Innovent Biologics（信达生物制药）

Established in 2011, Innovent is committed to developing, manufacturing and commercializing high quality innovative medicines for the treatment of major diseases such as cancer. On 31 October, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.

Since its inception, Innovent has developed a fully-integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 3 products, TYVYT® (sintilimab injection) , BYVASDA® (bevacizumab injection) and SULINNO® (adalimumab biosimilar), on market, 1 assets under NDA review with priority review status, 4 assets in Phase III or pivotal clinical trials, and additional 15 molecules in or close to clinical trials.TYVYT® has been the only PD-1 inhibitor included in the NRDL since 2019.

Innovent has built a biopharmaceutical production facility that operates under global standards. The design and operation of the clinical and commercial facilities are in compliance with the cGMP standards of NMPA, FDA and EMA. The existing production lines have already passed GMP audits by an international pharmaceutical company. Innovent has built an international team of advanced talents in high-end biological drug development and commercialization, including many overseas experts. The company has also entered into strategic cooperation with Eli Lilly, Adimab, Incyte, Hanmi and other international pharmaceutical companies.

Inspired by the spirit of "Start with Integrity, Succeed through Action”, Innovent’s mission is to develop and commercialize high quality biopharmaceutical products that are affordable to ordinary people.

Website	http://www.innoventbio.com
Employees	11-50 employees View all Innovent Biologics（信达生物制药） employees
Industry	pharmaceuticals
Location	Suzhou, Jiangsu, CN
Founded	2011
Keywords	Biologics Manufacturing, Monoclonal Antibodies, Biosimilars, Novel Drugs